
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics Inc. is positioned for positive growth due to its strategic focus on enhancing clinical updates and expanding strategic options for its pipeline, which includes promising compounds like VK2809, VK5211, and VK0214. The company's emphasis on orally available formulations, particularly VK2735, is expected to enhance patient compliance and treatment convenience, making it a strong contender in the obesity treatment market. Additionally, the anticipated differentiation of its products, along with potential monthly dosing regimens, is likely to attract favorable financing and partnering opportunities, underpinning a solid outlook for the company's future performance.
Bears say
Viking Therapeutics faces significant risks that could hinder its progress, primarily stemming from the potential for failed or inconclusive clinical trials and the challenge of securing sufficient funding for its drug development pipeline. The company operates in a volatile industry, characterized by regulatory uncertainty and unpredictable clinical outcomes, which could adversely impact its product candidates. Additionally, the increasing complexity and price sensitivity of commercial markets further complicate the landscape for Viking Therapeutics, potentially jeopardizing its financial performance and outlook.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares